Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.

The Journal of Immunology : Official Journal of the American Association of Immunologists
Stavroula BaritakiBenjamin Bonavida

Abstract

TRAIL promotes apoptotic tumor cell death; however, TRAIL-resistant tumors need to be sensitized to reverse resistance. Proteasome inhibitors potentiate TRAIL apoptosis in vitro and in vivo and correlate with up-regulation of death receptor 5 (DR5) via an unknown mechanism. We hypothesized that the proteasome inhibitor NPI-0052 inhibits the transcription repressor Yin Yang 1 (YY1) which regulates TRAIL resistance and negatively regulates DR5 transcription. Treatment of PC-3 and Ramos cells with NPI-0052 (</=2.5 nM) and TRAIL sensitizes the tumor cells to TRAIL-induced apoptosis. By comparison to bortezomib, a 400-fold less concentration of NPI-0052 was used. NPI-0052 up-regulated DR5 reporter activity and both surface and total DR5 protein expression. NPI-0052-induced inhibition of NF-kappaB activity was involved in TRAIL sensitization as corroborated by the use of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin. NPI-0052 inhibited YY1 promoter activity as well as both YY1 mRNA and protein expression. The direct role of NPI-0052-induced inhibition of YY1 and up-regulation of DR5 in the regulation of TRAIL sensitivity was demonstrated by the use of YY1 small interfering RNA. The NPI-0052-induced sensitization to TRAIL inv...Continue Reading

References

Jan 1, 1981·Advances in Cancer Research·M C Berenbaum
Aug 15, 2000·Leukemia·M S Sheikh, A J Fornace
Apr 24, 2001·International Journal of Radiation Oncology, Biology, Physics·S M RussoJ C Cusack
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Nov 25, 2003·Oncogene·Shulin Wang, Wafik S El-Deiry
Apr 28, 2004·Vitamins and Hormones·Nina-Beate Liabakk, Terje Espevik
Apr 28, 2004·Vitamins and Hormones·Bharat B AggarwalYasunari Takada
Jul 15, 2004·Current Opinion in Pharmacology·Sean K Kelley, Avi Ashkenazi
Aug 4, 2004·Cancer Research·Christos N Papandreou, Christopher J Logothetis
Aug 24, 2004·The Journal of Biological Chemistry·Hirohito Yamaguchi, Hong-Gang Wang
Sep 24, 2004·Cancer Cell·Bharat B Aggarwal
Oct 27, 2004·Cancer Science·Hideo YagitaKo Okumura
Dec 2, 2004·Journal of the National Cancer Institute·Xiangguo LiuShi-Yong Sun
May 27, 2005·Journal of Medicinal Chemistry·Venkat R MacherlaBarbara C M Potts
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alessio NencioniAlberto Ballestrero
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jan 24, 2006·Critical Reviews in Oncology/hematology·Giorgio Scagliotti
May 16, 2006·Apoptosis : an International Journal on Programmed Cell Death·Albert F KaboreSpencer B Gibson
Sep 21, 2006·Molecular Cancer Therapeutics·Sanaz KhanbolookiDavid J McConkey
Nov 11, 2006·Leukemia·A NencioniP Brossart
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James C CusackMichael A Palladino
Dec 19, 2006·Molecular Cancer Therapeutics·Mark J WilliamsonMark Rolfe
Jan 26, 2007·Apoptosis : an International Journal on Programmed Cell Death·Ernestina SaulleUgo Testa
Mar 1, 2007·The Journal of Clinical Endocrinology and Metabolism·Concetta ConticelloRuggero De Maria
Apr 18, 2007·Molecular and Cellular Biology·Huating WangDenis C Guttridge

❮ Previous
Next ❯

Citations

Nov 20, 2009·European Journal of Haematology·Lia E PerezWilliam Dalton
Jan 26, 2011·Cancer Biology & Therapy·Hope M AmmDonald J Buchsbaum
Sep 2, 2014·Molecular Medicine Reports·Angeles Hernandez-CuetoSara Huerta-Yepez
Dec 21, 2010·American Journal of Respiratory and Critical Care Medicine·Xin LinJia Guo
Jun 28, 2012·International Journal of Oncology·Ewelina SzliszkaWojciech Krol
Apr 18, 2015·Frontiers in Oncology·Rachana Trivedi, Durga Prasad Mishra
Aug 26, 2020·Genes and Immunity·Michael Basler, Marcus Groettrup
Apr 21, 2012·Pharmacogenomics·Christina JustenhovenHiltrud Brauch
Jun 7, 2014·Expert Opinion on Investigational Drugs·Sara BringhenAntonio Palumbo
Mar 13, 2018·Advanced Healthcare Materials·Yesi ShiGang Liu
Jan 12, 2019·Archives of Pharmacal Research·Kyoung-Jin MinTaeg Kyu Kwon
Dec 12, 2019·Frontiers in Oncology·Sailu SarvagallaSivakumar Vallabhapurapu
Feb 13, 2009·Apoptosis : an International Journal on Programmed Cell Death·Han-Ming Shen, Vinay Tergaonkar
Nov 27, 2019·Biomolecules·Maria Gabriela-FreitasOlga Martinho
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Filomena de NigrisClaudio Napoli
Oct 29, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ross L PrenticeDennis G Ballinger
Jan 9, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ross L PrenticeDennis G Ballinger
Sep 10, 2008·Nitric Oxide : Biology and Chemistry·Sara Huerta-YepezBenjamin Bonavida
Dec 29, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·J H StegehuisF A E Kruyt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis